Showing results (31-40 of 65) with videos related to
Sort By:
Pageof 7
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 21, 2010
Bortezomib plus dexamethasone induction improves outcome of patients with t(4;14) myeloma but not outcome of patients with del(17p)Hervé Avet-Loiseau, Xavier Leleu, Murielle Roussel, et al.Leukemia|February 1, 2020
Daratumumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: extended follow-up of POLLUX, a randomized, open-label, phase 3 studyNizar J Bahlis, Meletios A Dimopoulos, Darrell J White, et al.Haematologica|May 2, 2020
Subcutaneous daratumumab in patients with relapsed or refractory multiple myeloma: Part 2 of the open-label, multicenter, dose-escalation phase 1b study (PAVO)Jesus San-Miguel, Saad Z Usmani, Maria-Victoria Mateos, et al.European Journal of Haematology|October 26, 2011
Low-dose vs. high-dose thalidomide for advanced multiple myeloma: a prospective trial from the Intergroupe Francophone du MyélomeIbrahim Yakoub-Agha, Jean-Yves Mary, Cyrille Hulin, et al.Haematologica|June 22, 2019
Daratumumab-based regimens are highly effective and well tolerated in relapsed or refractory multiple myeloma regardless of patient age: subgroup analysis of the phase 3 CASTOR and POLLUX studiesMaria-Victoria Mateos, Andrew Spencer, Ajay K Nooka, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2014
Front-line transplantation program with lenalidomide, bortezomib, and dexamethasone combination as induction and consolidation followed by lenalidomide maintenance in patients with multiple myeloma: a phase II study by the Intergroupe Francophone du MyélomeMurielle Roussel, Valérie Lauwers-Cances, Nelly Robillard, et al.Oncotarget|May 31, 2018
Phase I dose-escalation study of F50067, a humanized anti-CXCR4 monoclonal antibody alone and in combination with lenalidomide and low-dose dexamethasone, in relapsed or refractory multiple myelomaGuillemette Fouquet, Stéphanie Guidez, Valentine Richez, et al.American Journal of Hematology|March 13, 2019
Apixaban for the prevention of thromboembolism in immunomodulatory-treated myeloma patients: Myelaxat, a phase 2 pilot studyBrigitte Pegourie, Lionel Karlin, Lotfi Benboubker, et al.JAMA|December 7, 2017
Effect of High-Cutoff Hemodialysis vs Conventional Hemodialysis on Hemodialysis Independence Among Patients With Myeloma Cast Nephropathy: A Randomized Clinical TrialFrank Bridoux, Pierre-Louis Carron, Brigitte Pegourie, et al.Ejhaem|November 29, 2023
Late versus early response and depth of response are associated with improved outcomes in patients with newly diagnosed multiple myeloma enrolled in the TOURMALINE-MM2 trialPaul G Richardson, Thierry Facon, Christopher P Venner, et al.Pageof 7